Ann: Financial Results for Quarter Ending 30 June 2024, page-27

I cannot understand the strategy of management here. Looks like we are trying to become a sales company than biotech company. We employ so many sales people and now making collaboration with other start ups to prove the decision is right one.
Margins are high but the expenses are even higher. Why cannot we sell our rights to another sales and marketing organisation and enjoy royalties than becoming another sales and marketing organisation.
A lot of pressure is coming on vitiligo treatment commercialisation. If everything goes as plan then Avita is going to the moon otherwise it looks more like a spending machine in present scenario.
Company is projecting break even by 3rd quarter of 2025 that means we have to wait only 5 more quarters now. It is a long wait but may be worth the effort.
dyor